BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salvador B, Sexton NR, Carrion R Jr, Nunneley J, Patterson JL, Steffen I, Lu K, Muench MO, Lembo D, Simmons G. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol 2013;87:3295-304. [PMID: 23302881 DOI: 10.1128/JVI.01621-12] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Schafer A, Xiong R, Cooper L, Nowar R, Lee H, Li Y, Ramirez BE, Peet NP, Caffrey M, Thatcher GRJ, Saphire EO, Cheng H, Rong L. Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. PLoS Pathog 2021;17:e1009312. [PMID: 33539432 DOI: 10.1371/journal.ppat.1009312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Murakami S, Takenaka-Uema A, Kobayashi T, Kato K, Shimojima M, Palmarini M, Horimoto T. Heparan Sulfate Proteoglycan Is an Important Attachment Factor for Cell Entry of Akabane and Schmallenberg Viruses. J Virol 2017;91:e00503-17. [PMID: 28539443 DOI: 10.1128/JVI.00503-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
3 Cui Q, Du R, Anantpadma M, Schafer A, Hou L, Tian J, Davey RA, Cheng H, Rong L. Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor. Viruses 2018;10:E152. [PMID: 29584652 DOI: 10.3390/v10040152] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
4 Ke F, Wang ZH, Ming CY, Zhang QY. Ranaviruses Bind Cells from Different Species through Interaction with Heparan Sulfate. Viruses 2019;11:E593. [PMID: 31261956 DOI: 10.3390/v11070593] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res 2015;4:30. [PMID: 26069727 DOI: 10.12688/f1000research.6085.2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
6 Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 2015;116:76-84. [PMID: 25666761 DOI: 10.1016/j.antiviral.2015.01.011] [Cited by in Crossref: 338] [Cited by in F6Publishing: 324] [Article Influence: 48.3] [Reference Citation Analysis]
7 Lima M, Rudd T, Yates E. New Applications of Heparin and Other Glycosaminoglycans. Molecules 2017;22:E749. [PMID: 28481236 DOI: 10.3390/molecules22050749] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
8 Escaffre O, Juelich TL, Freiberg AN. Polyphenylene carboxymethylene (PPCM) in vitro antiviral efficacy against Ebola virus in the context of a sexually transmitted infection. Antiviral Res 2019;170:104567. [PMID: 31351092 DOI: 10.1016/j.antiviral.2019.104567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Jiang J, Wu X, Tang H, Luo G. Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. PLoS One. 2013;8:e67982. [PMID: 23844141 DOI: 10.1371/journal.pone.0067982] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
10 Cagno V, Tseligka ED, Jones ST, Tapparel C. Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias? Viruses 2019;11:E596. [PMID: 31266258 DOI: 10.3390/v11070596] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 34.3] [Reference Citation Analysis]
11 Bramble MS, Hoff N, Gilchuk P, Mukadi P, Lu K, Doshi RH, Steffen I, Nicholson BP, Lipson A, Vashist N, Sinai C, Spencer D, Olinger G, Wemakoy EO, Illunga BK, Pettitt J, Logue J, Marchand J, Varughese J, Bennett RS, Jahrling P, Cavet G, Serafini T, Ollmann Saphire E, Vilain E, Muyembe-Tamfum JJ, Hensely LE, Simmons G, Crowe JE Jr, Rimoin AW. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors. J Infect Dis 2018;218:1929-36. [PMID: 30107445 DOI: 10.1093/infdis/jiy453] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
12 Bauer S, Zhang F, Linhardt RJ. Implications of Glycosaminoglycans on Viral Zoonotic Diseases. Diseases 2021;9:85. [PMID: 34842642 DOI: 10.3390/diseases9040085] [Reference Citation Analysis]
13 Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res 2015;4:30. [PMID: 26069727 DOI: 10.12688/f1000research.6085.2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
14 Steffen I, Lu K, Hoff NA, Mulembakani P, Okitolonda Wemakoy E, Muyembe-Tamfum JJ, Ndembi N, Brennan CA, Hackett J Jr, Switzer WM, Saragosti S, Mbensa GO, Laperche S, Rimoin AW, Simmons G. Seroreactivity against Marburg or related filoviruses in West and Central Africa. Emerg Microbes Infect 2020;9:124-8. [PMID: 31913767 DOI: 10.1080/22221751.2019.1709563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lopes AM, Breiman A, Lora M, Le Moullac-Vaidye B, Galanina O, Nyström K, Marchandeau S, Le Gall-Reculé G, Strive T, Neimanis A, Bovin NV, Ruvoën-Clouet N, Esteves PJ, Abrantes J, Le Pendu J. Host-Specific Glycans Are Correlated with Susceptibility to Infection by Lagoviruses, but Not with Their Virulence. J Virol 2018;92:e01759-17. [PMID: 29187537 DOI: 10.1128/JVI.01759-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Martin B, Hoenen T, Canard B, Decroly E. Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry. Antiviral Res 2016;135:1-14. [PMID: 27640102 DOI: 10.1016/j.antiviral.2016.09.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
17 Thieker DF, Xu Y, Chapla D, Nora C, Qiu H, Felix T, Wang L, Moremen KW, Liu J, Esko JD, Woods RJ. Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-Sulfotransferase. Sci Rep 2018;8:11832. [PMID: 30087361 DOI: 10.1038/s41598-018-29602-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Cagno V, Donalisio M, Civra A, Volante M, Veccelli E, Oreste P, Rusnati M, Lembo D. Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures. Antimicrob Agents Chemother 2014;58:4782-94. [PMID: 24914125 DOI: 10.1128/AAC.02594-14] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
19 Gao Y, Cheng H, Khan S, Xiao G, Rong L, Bai C. Development of coumarine derivatives as potent anti-filovirus entry inhibitors targeting viral glycoprotein. Eur J Med Chem 2020;204:112595. [PMID: 32707357 DOI: 10.1016/j.ejmech.2020.112595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lachmann PJ. Traditional passive immune therapy for emerging Ebola infection. Emerg Microbes Infect 2014;3:e81. [PMID: 26038503 DOI: 10.1038/emi.2014.87] [Reference Citation Analysis]
21 Rebensburg S, Helfer M, Schneider M, Koppensteiner H, Eberle J, Schindler M, Gürtler L, Brack-Werner R. Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins. Sci Rep 2016;6:20394. [PMID: 26833261 DOI: 10.1038/srep20394] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
22 O'Hearn A, Wang M, Cheng H, Lear-Rooney CM, Koning K, Rumschlag-Booms E, Varhegyi E, Olinger G, Rong L. Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry. J Virol 2015;89:5441-9. [PMID: 25741008 DOI: 10.1128/JVI.03689-14] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
23 Altgärde N, Eriksson C, Peerboom N, Phan-Xuan T, Moeller S, Schnabelrauch M, Svedhem S, Trybala E, Bergström T, Bally M. Mucin-like Region of Herpes Simplex Virus Type 1 Attachment Protein Glycoprotein C (gC) Modulates the Virus-Glycosaminoglycan Interaction. J Biol Chem 2015;290:21473-85. [PMID: 26160171 DOI: 10.1074/jbc.M115.637363] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
24 Cooper L, Schafer A, Li Y, Cheng H, Medegan Fagla B, Shen Z, Nowar R, Dye K, Anantpadma M, Davey RA, Thatcher GRJ, Rong L, Xiong R. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem 2020;63:11085-99. [PMID: 32886512 DOI: 10.1021/acs.jmedchem.0c01001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Henß L, Beck S, Weidner T, Biedenkopf N, Sliva K, Weber C, Becker S, Schnierle BS. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry. Virol J 2016;13:149. [PMID: 27581733 DOI: 10.1186/s12985-016-0607-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
26 Schafer A, Cheng H, Xiong R, Soloveva V, Retterer C, Mo F, Bavari S, Thatcher G, Rong L. Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. Antiviral Res 2018;157:47-56. [PMID: 29981374 DOI: 10.1016/j.antiviral.2018.07.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
27 Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger GG Jr, White JM. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Negl Trop Dis 2017;11:e0005540. [PMID: 28403145 DOI: 10.1371/journal.pntd.0005540] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 11.2] [Reference Citation Analysis]
28 Bon I, Lembo D, Rusnati M, Clò A, Morini S, Miserocchi A, Bugatti A, Grigolon S, Musumeci G, Landolfo S, Re MC, Gibellini D. Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. PLoS One 2013;8:e76482. [PMID: 24116111 DOI: 10.1371/journal.pone.0076482] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
29 Cheng H, Schafer A, Soloveva V, Gharaibeh D, Kenny T, Retterer C, Zamani R, Bavari S, Peet NP, Rong L. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor. Antiviral Res 2017;145:24-32. [PMID: 28645623 DOI: 10.1016/j.antiviral.2017.06.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
30 Peerboom N, Block S, Altgärde N, Wahlsten O, Möller S, Schnabelrauch M, Trybala E, Bergström T, Bally M. Binding Kinetics and Lateral Mobility of HSV-1 on End-Grafted Sulfated Glycosaminoglycans. Biophys J 2017;113:1223-34. [PMID: 28697896 DOI: 10.1016/j.bpj.2017.06.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
31 Klimyte EM, Smith SE, Oreste P, Lembo D, Dutch RE. Inhibition of Human Metapneumovirus Binding to Heparan Sulfate Blocks Infection in Human Lung Cells and Airway Tissues. J Virol 2016;90:9237-50. [PMID: 27489270 DOI: 10.1128/JVI.01362-16] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
32 Tamhankar M, Gerhardt DM, Bennett RS, Murphy N, Jahrling PB, Patterson JL. Heparan sulfate is an important mediator of Ebola virus infection in polarized epithelial cells. Virol J 2018;15:135. [PMID: 30165875 DOI: 10.1186/s12985-018-1045-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
33 Steffen I, Liss NM, Schneider BS, Fair JN, Chiu CY, Simmons G. Characterization of the Bas-Congo virus glycoprotein and its function in pseudotyped viruses. J Virol 2013;87:9558-68. [PMID: 23785218 DOI: 10.1128/JVI.01183-13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
34 Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. J Virol. 2015;89:9932-9938. [PMID: 26202243 DOI: 10.1128/jvi.01337-15] [Cited by in Crossref: 67] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
35 Raaben M, Jae LT, Herbert AS, Kuehne AI, Stubbs SH, Chou YY, Blomen VA, Kirchhausen T, Dye JM, Brummelkamp TR, Whelan SP. NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry. Cell Host Microbe 2017;22:688-696.e5. [PMID: 29120745 DOI: 10.1016/j.chom.2017.10.002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]